We have compiled a list of manufacturers, distributors, product information, reference prices, and rankings for Biomarkers.
ipros is IPROS GMS ・ IPROS One of the largest technical database sites in Japan that collects information on.

Biomarkers - List of Manufacturers, Suppliers, Companies and Products

Biomarkers Product List

1～8 item / All 8 items

Displayed results
Hirosaki University Technology: Diagnostic Biomarker for Urothelial Carcinoma: K23-016

Hirosaki University Technology: Diagnostic Biomarker for Urothelial Carcinoma: K23-016

Discovery of N-linked glycan mutations in serum Ig specific to urothelial carcinoma.

The present invention relates to a diagnostic biomarker for urinary tract urothelial carcinoma based on serum immunoglobulin (Ig) N-binding glycan structural mutations. The diagnosis of urinary tract urothelial carcinoma (bladder cancer and renal pelvis/ureter cancer) is performed through urine cytology, imaging diagnostics, and invasive procedures such as cystoscopy and ureteroscopy with biopsy. However, the sensitivity and specificity are not sufficient, and there is a demand for a novel non-invasive marker that can detect urinary tract urothelial carcinoma at an early stage. Therefore, the inventors identified urinary tract urothelial carcinoma-specific glycan mutations and demonstrated that the disease can be detected with high accuracy by scoring the related glycans (see right figure). Additionally, they identified two types of lectins that can distinguish upper urinary tract urothelial carcinoma using a lectin array, enabling the entire process from serum collection to analysis to be completed in four hours. 【Advantages over prior art】 - As a serum marker, it is less invasive than cystoscopy. - Diagnostic accuracy far exceeds that of urine cytology, with AUC > 0.9. - Intended for use as an early diagnostic marker for urinary tract urothelial carcinoma.

  • others

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Tohoku University Technology: Diagnostic Marker for Optic Nerve Disorders: T17-035

Tohoku University Technology: Diagnostic Marker for Optic Nerve Disorders: T17-035

Identifying markers from samples of glaucoma model mice. Currently acquiring human clinical sample data.

A representative example of optic nerve disorders is glaucoma. Glaucoma has no subjective symptoms, so patients may not notice it as the condition progresses, potentially leading to blindness in the worst cases. Traditionally, the diagnosis of glaucoma has primarily involved fundus examinations, which are not easy methods and are not high-throughput diagnostic methods. The inventors conducted metabolome analysis using the retinas of glaucoma model mice (optic nerve crush mice) and identified several markers that change with the progression of glaucoma. The identified markers are expected to be utilized as markers for optic nerve disorders such as glaucoma. Currently, data is being collected from human clinical samples (such as blood). There are unpublished data (human blood sample data).

  • others

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Tohoku University Technology: Prognostic Biomarker for Cancer Patients: T20-3069

Tohoku University Technology: Prognostic Biomarker for Cancer Patients: T20-3069

The expression level of LILRB4 can accurately predict the prognosis of cancer patients.

The immunosuppressive receptor LILRB4 (B4) is one of the immune checkpoint (CP) molecules that has garnered attention in cancer treatment, particularly represented by PD-1, but its true ligand has remained unknown. In the prior application of the inventors (related literature 1), a novel immune CP inhibitor and a therapeutic agent containing it were provided based on the discovery of the physiological ligand fibronectin (FN) for B4 and the finding that immune regulation is possible by inhibiting B4-FN binding. In the present invention, a monoclonal antibody that inhibits FN binding to B4 was uniquely developed, and the prognostic prediction of lung cancer patients using B4 as a biomarker was validated. That is, by early identification of the poor prognosis group, it is possible to support appropriate selection of treatments such as immune checkpoint inhibitor therapy.

  • others

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
[Research Material] Global Market for Stroke Biomarkers

[Research Material] Global Market for Stroke Biomarkers

Global Market for Stroke Biomarkers: Blood Biomarkers, Urine Biomarkers, Diagnostics, Drug Development, Personalized Medicine, and Others

This research report (Global Stroke Testing Biomarkers Market) investigates and analyzes the current status and outlook for the global market of stroke testing biomarkers over the next five years. It includes information on the overview of the global stroke testing biomarkers market, trends of major companies (sales, selling prices, market share), market size by segment, market size by major regions, and distribution channel analysis. The market segments by type include blood biomarkers and urine biomarkers, while the segments by application cover diagnosis, drug development, personalized medicine, and others. The regional segments are categorized into North America, the United States, Europe, Asia-Pacific, Japan, China, India, South Korea, Southeast Asia, South America, the Middle East, and Africa, to calculate the market size of stroke testing biomarkers. It also includes the market share of major companies in the stroke testing biomarkers sector, product and business overviews, and sales performance.

  • Other services

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
[Research Material] Global Market for Diagnostic Exosome Biomarkers

[Research Material] Global Market for Diagnostic Exosome Biomarkers

World Market for Diagnostic Exosome Biomarkers: Membrane-Bound Proteins, Soluble Proteins, Non-Coding RNA, Others, Hospitals, C...

This research report (Global Diagnostic Exosome Biomarker Market) investigates and analyzes the current status and outlook for the global market of diagnostic exosome biomarkers over the next five years. It includes information on the overview of the global diagnostic exosome biomarker market, trends of major companies (sales, selling prices, market share), market size by segment, market size by major regions, and distribution channel analysis. The segments by type in the diagnostic exosome biomarker market include membrane-bound proteins, soluble proteins, non-coding RNA, and others, while the segments by application focus on hospitals, clinics, and outpatient surgery centers. The regional segments are divided into North America, the United States, Europe, Asia-Pacific, Japan, China, India, South Korea, Southeast Asia, South America, the Middle East, and Africa to calculate the market size of diagnostic exosome biomarkers. The report also includes the market share of major companies in the diagnostic exosome biomarker sector, product and business overviews, and sales performance.

  • Other services

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
[Research Material] Global Market for Diagnostic Biomarkers

[Research Material] Global Market for Diagnostic Biomarkers

Global Market for Diagnostic Biomarkers: Safety Biomarkers, Efficacy Biomarkers, Verification Biomarkers, Hospitals, Cancer Research Institutes, Diagnostic Research Institutes

This research report (Global Diagnostic Biomarkers Market) investigates and analyzes the current state and future outlook of the global diagnostic biomarkers market over the next five years. It includes information on the overview of the global diagnostic biomarkers market, trends of major companies (sales, selling prices, market share), market size by segment, market size by major regions, and distribution channel analysis. The segments by type in the diagnostic biomarkers market focus on safety biomarkers, efficacy biomarkers, and verification biomarkers, while the segments by application target hospitals, cancer research institutes, and diagnostic research laboratories. The regional segments are divided into North America, the United States, Europe, Asia-Pacific, Japan, China, India, South Korea, Southeast Asia, South America, the Middle East, and Africa, to calculate the market size for diagnostic biomarkers. It also includes the market share of major companies in the diagnostic biomarkers sector, product and business overviews, and sales performance.

  • Other services

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
[Market Report] Global Market for Cancer Biomarkers

[Market Report] Global Market for Cancer Biomarkers

The global market for cancer biomarkers is expected to achieve significant growth, surpassing 36.2 billion USD by 2031, with an average annual growth rate of 13%.

The global cancer biomarker market is experiencing remarkable growth driven by advancements in personalized medicine, early detection technologies, and increasing attention to precision oncology. The market size in 2022 was 12.7 billion USD, and this dynamic market is expected to expand significantly, exceeding 36.2 billion USD by 2031. This growth is projected to be supported by a robust compound annual growth rate (CAGR) of 13% during the forecast period from 2023 to 2031. Cancer biomarkers have emerged as essential tools that enhance the accuracy of cancer diagnosis, prognosis, and treatment selection. These molecular indicators provide valuable insights into the patient-specific genetic makeup, enabling healthcare professionals to develop tailored treatment strategies that improve outcomes and reduce side effects. Please check the application method via the [PDF download] button or apply directly through the related links.

  • others

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
[Market Report] Global Market for Neurobiomarkers

[Market Report] Global Market for Neurobiomarkers

The global market for neuro biomarkers is expected to surge, reaching 22.1 billion USD by 2031.

The global neurological biomarker market is experiencing significant rapid growth and is expected to see substantial expansion in the coming years. In 2022, the market achieved revenues of approximately 7.39 billion USD. It is projected to reach 22.1 billion USD by 2031, indicating a strong outlook for market expansion. This robust growth trajectory is supported by a steady compound annual growth rate (CAGR) of 13% during the forecast period from 2023 to 2031. For application methods, please check the [PDF download] button or apply directly through the related links.

  • others

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Related Categories of Biomarkers

COPYRIGHT © 2001-2026 IPROS CORPORATION ALL RIGHTS RESERVED.